Jump Financial’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Jump Financial’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-45,868	Closed	-$1.2M	–	2173
2022 Q4	$1.2M	Buy	45,868 +2,234	+5%	+$49.5K	0.06%	399
2022 Q3	$858K	Buy	43,634 +33,575	+334%	+$673K	0.03%	672
2022 Q2	$176K	Sell	10,059 -18,141	-64%	-$285K	0.01%	1339
2022 Q1	$461K	Buy	+28,200	New	+$383K	0.02%	854
2021 Q4	–	Sell	-17,000	Closed	-$217K	–	1825
2021 Q3	$217K	Buy	+17,000	New	+$224K	0.02%	829

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Jump Financial's KDNY Position: Q1 2023 in Review

Jump Financial sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2023, closing a stake of 45,868 shares — an estimated $1.2M sold.

Jump Financial first reported a position in KDNY in Q3 2021 and held it in 5 quarters. The position peaked at $1.2M in Q4 2022. 157 funds tracked by Wall St. Rank hold KDNY as of Q1 2023.

Jump Financial reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Jump Financial sold 45,868 Chinook Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.2M.
Jump Financial first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2021 and held it in 5 quarters.
Jump Financial's Chinook Therapeutics, Inc. Common Stock position peaked at $1.2M in Q4 2022.
157 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Jump Financial's 13F filing for Q1 2023, filed 3 May 2023.